Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology

Y Collins, K Holcomb, E Chapman-Davis… - Gynecologic …, 2014 - Elsevier
Objectives To review the extent of health disparities in gynecologic cancer care and
outcomes and to propose recommendations to help counteract the disparities. Methods We …

Adenosquamous histology predicts a poor outcome for patients with advanced‐stage, but not early‐stage, cervical carcinoma

JH Farley, KW Hickey, JW Carlson… - … Journal of the …, 2003 - Wiley Online Library
BACKGROUND The objective of this study was to compare survival between patients with
adenocarcinoma and patients with adenosquamous carcinoma of the cervix. METHODS …

MEK1/2 inhibitors in the treatment of gynecologic malignancies

CR Miller, KE Oliver, JH Farley - Gynecologic oncology, 2014 - Elsevier
Mitogen-activated protein kinases (MAPKs) are a family of ubiquitous eukaryotic signal
transduction enzymes which link extracellular stimuli to intracellular gene expression …

Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4

P Ramos, AN Karnezis, DW Craig, A Sekulic… - Nature …, 2014 - nature.com
Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is an extremely rare,
aggressive cancer affecting children and young women. We identified germline and somatic …

Factors associated with survival disparities between non-Hispanic Black and White patients with uterine cancer

CW Kucera, C Tian, CM Tarney, C Presti… - JAMA network …, 2023 - jamanetwork.com
Importance Disparities in survival exist between non-Hispanic Black (hereafter, Black) and
non-Hispanic White (hereafter, White) patients with uterine cancer. Objective To investigate …

[HTML][HTML] A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)

GJ Weiss, J Waypa, L Blaydorn, J Coats… - British journal of …, 2017 - nature.com
Background: Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction
between programmed cell death protein 1 (PD-1) on T-cells and PD-L1 and PD-L2 on …

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum …

KE Oliver, WE Brady, M Birrer, DM Gershenson… - Gynecologic …, 2017 - Elsevier
Purpose We examined disparities in prognosis between patients with ovarian clear cell
carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods We reviewed data …

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

CA Hamilton, GL Maxwell, MR Chernofsky… - Gynecologic …, 2008 - Elsevier
BACKGROUND: Malignant ascites often has a profound impact on the quality of life of
patients with refractory ovarian cancer. Current treatments, including dietary, medical, and …

Equal care ensures equal survival for African‐American women with cervical carcinoma

JH Farley, JF Hines, RR Taylor, JW Carlson… - Cancer, 2001 - Wiley Online Library
BACKGOUND. It was the purpose of this study to investigate whether race is an independent
prognostic factor in the survival of patients with cervical carcinoma in a health care system …

Promoting health equity in the era of COVID-19

JH Farley, J Hines, NK Lee… - Gynecologic …, 2020 - gynecologiconcology-online.net
Across the United States, it is now apparent that the COVID-19 virus is exacerbating existing
societal biases and longstanding inequities in health care, resulting in an excess of …